PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28424891-14 2017 Overlapping toxicities prevented the escalation of selumetinib to its recommended phase II monotherapy dose of 75 mg BID. AZD 6244 51-62 BH3 interacting domain death agonist Homo sapiens 117-120 29136201-13 2018 Selumetinib 75 mg BID plus docetaxel 60 mg/m2 was not tolerated in this patient population. AZD 6244 0-11 BH3 interacting domain death agonist Homo sapiens 18-21 28264648-6 2017 Part A of the study (dose escalation) evaluated safety, tolerability, PK, and maximum tolerated dose (MTD) of selumetinib twice daily (BID) with docetaxel 75 mg/m2 or dacarbazine 1000 mg/m2 administered every 21 days. AZD 6244 110-121 BH3 interacting domain death agonist Homo sapiens 135-138